Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing antiHIV1 monoclonal antibodies bNAbs given to HIV1 exposed uninfected neonates and infants study protocol for a phase I trial

dc.article.end-page17en
dc.article.start-page1en
dc.citation.doi10.1186/S12879-024-09588-3en
dc.contributor.authorA Gogaen
dc.contributor.authorTrisha Ramrajen
dc.contributor.authorLogashvari Naidooen
dc.contributor.authorBrodie Danielsen
dc.contributor.authorPenelope Mooreen
dc.contributor.authorNonhlanhla Mkhizeen
dc.contributor.authorE et alen
dc.date.accessioned2025-01-22T11:52:40Z
dc.date.available2025-01-22T11:52:40Z
dc.facultyFACULTY OF HEALTH SCIENCESen
dc.identifier.citationWOSen
dc.identifier.issn1471-2334en
dc.identifier.urihttps://hdl.handle.net/10539/43619
dc.journal.titleSafety and pharmacokinetics of subcutaneous administration of broadly neutralizing antiHIV1 monoclonal antibodies bNAbs given to HIV1 exposed uninfected neonates and infants study protocol for a phase I trialen
dc.journal.volume24en
dc.publisherBIOMED CENTRAL LTDen
dc.titleSafety and pharmacokinetics of subcutaneous administration of broadly neutralizing antiHIV1 monoclonal antibodies bNAbs given to HIV1 exposed uninfected neonates and infants study protocol for a phase I trialen
dc.typeJournal Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Journal Article.pdf
Size:
1.28 MB
Format:
Adobe Portable Document Format
Description:
Bitstream uploaded by REST Client